Manipulation of Schlemm's effective in treating glaucoma

Article

According to Manfred Tetz and colleagues, Germany, dilation and tensioning of Schlemm's canal may be an effective, non-penetrating surgical method for the treatment of open angle glaucoma (OAG).

According to Manfred Tetz and colleagues, Germany, dilation and tensioning of Schlemm's canal may be an effective, non-penetrating surgical method for the treatment of open angle glaucoma (OAG).

The authors conducted a multicentre, prospective clinical study at three German outpatient surgical centres to determine the safety and efficacy of dilation and tensioning of Schlemm's canal during non-penetrating surgery in glaucoma patients.

A flexible microcannula was introduced into the canal, following surgical exposure, to perform viscodilation of the canal and associated collector channels. The microcannula was used, after 360 degrees of canal cannulation, to insert a 10-0 prolene suture to tension the inner wall of the canal and related trabecular meshwork. Postoperatively, subjects were examined to evaluate the anterior segment and intraocular pressure (IOP), a number of patients were also examined using high resolution ultrasound imaging of the anterior segment angle to evaluate the Schlemm's canal morphology.

To date, the results from 71 subjects have been gathered. Tensioning sutures were observed to distend the inner wall of the canal and trabecular meshwork, whilst also maintaining the canal lumen. Average IOP at six months follow up (n=26) was 14.4 mmHg with an average of 0.2 medications being used. Just four subjects reported adverse events.

Tetz and co-workers noted that viscodilation of the canal restored physiologic drainage and controlled IOP levels. Consequently, they concluded that dilation and tensioning could be an effective non-penetrating surgical method for the treatment of OAG.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.